Temozolomide down-regulates P-glycoprotein in human blood-brain barrier cells by disrupting Wnt3 signaling

Cellular and Molecular Life Sciences

Volumn 71, Issue 3, 2014, Pages 499-516

  Riganti, Chiara ^a,b   Salaroglio, Iris C ^a   Pinzòn Daza, Martha L ^a,c   Caldera, Valentina ^d   Campia, Ivana ^a   Kopecka, Joanna ^a   Mellai, Marta ^d   Annovazzi, Laura ^d   Couraud, Pierre Olivier ^e   Bosia, Amalia ^a,b   Ghigo, Dario ^a,b   Schiffer, Davide ^d  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSIDAD DEL ROSARIO   (Colombia)

^d Neuro bio oncology Center   (Italy)

^e INSTITUT COCHIN   (France)

Author keywords

Blood brain barrier; Glioblastoma multiforme; P glycoprotein; Temozolomide; Wnt3

Indexed keywords

ABC TRANSPORTER; BETA CATENIN; BETA TUBULIN; CASPASE 3; CLAUDIN 3; CLAUDIN 5; DOXORUBICIN; GLYCOGEN SYNTHASE KINASE 3; HOE 33342; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; OCCLUDIN; PROTEIN ZO1; RHODAMINE 123; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CELL COUNT; CELL PERMEABILIZATION; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFICACY; DRUG PENETRATION; GENE; GENETIC TRANSCRIPTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MDR1 GENE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; WNT SIGNALING PATHWAY;

ANTINEOPLASTIC AGENTS; BETA CATENIN; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; CELL LINE, TUMOR; DACARBAZINE; DNA METHYLATION; GENE EXPRESSION REGULATION; HUMANS; P-GLYCOPROTEIN; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; WNT3 PROTEIN;

EID: 84892814270     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-013-1397-y     Document Type: Article

References (43)

1. Bai RY, Staedke V, Riggins GJ (2011) Molecular targeting of GBM: drug discovery and therapies. Trends Mol Med 17:301-332
2. Serwer LP, James CD (2012) Challenges in drug delivery to tumors of the central nervous system: an overview of pharmacological and surgical considerations. Adv Drug Deliv Rev 64:590-597
3. Saleem A, Brown GD, Brady F, Aboagye EO, Osman S, Luthra SK, Ranicar AS, Brock CS, Stevens MF, Newlands E, Jones T, Price P (2003) Metabolic activation of temozolomide measured in vivo using positron emission tomography. Cancer Res 63:2409-2415 (Pubitemid 36605177)
4. Wick W, Plattan M, Weller M (2009) New (alternative) temozolomide regimens fort he treatment of glioma. Neuro Oncol 11:69-79
5. Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon JE 2nd, Marcello J, Kirkpatrick JP, Sampson JH, Bailey L, Threatt S, Friedman AH, Bigner DD, Friedman HS (2011) The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res 17:4119-4124
6. Lopez KA, Tannenbaum AM, Assanah MC, Linskey K, Yun J, Kangarlu A, Gil OD, Canoli P, Bruce JN (2011) Convection-enhanced delivery of topotecan into PDGF-driven model of glioblastoma prolongs survival and ablates both tumor-initiating cells recruited glial progenitors. Cancer Res 71:3963-3971
7. Hau P, Fabel K, Baumgart U, Rummele P, Grauer O, Bock A, Dietmaier C, Dietmaier W, Dietrich J, Dudel C, Hubner F, Jaucj T, Drechsel E, Kleiter I, Wismeth C, Zellner A, Brawanski A, Steinbrecher A, Marienhagen J, Bogdahan U (2004) PEGylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 100:1199-1207 (Pubitemid 38325948)
8. Agarwal S, Sane R, Oberoi R, Ohlfest JR, Elmquist WF (2011) Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med 13:e17
9. Guillaume DJ, Doolittle ND, Gahramanov S, Hedrick NA, Delashaw JB, Neuwelt EA (2010) Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study. Neurosurgery 66:48-58
10. Liu H-L, Hua M-Y, Chen P-Y, Chu P-C, Pan C-H, Yang H-W, Wuang C-Y, Wang J-J, Yen T-C, Wei K-C (2010) Blood-brain barrier disruption with focused ultrasound enhanced delivery of chemotherapeutic drugs for glioblastoma treatment. Radiology 255:415-425
11. Agarwal S, Hartz AM, Elmquist WF, Bauer B (2011) Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm Des 17:2793-2802
12. Poller B, Drewe J, Krähenbühl S, Huwyler J, Gutmann H (2010) Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier. Cell Mol Neurobiol 30:63-70
13. Chan GNY, Hoque MT, Cummins CL, Bendayan R (2011) Regulation of P-glycoprotein by orphan nuclear receptors in human brain microvessel endothelial cells. J Neurochem 118:163-175
14. Wang X, Hawkins BT, Miller DS (2011) Aryl hydrocarbon receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. FASEB J 25:644-652
15. Daneman R, Agalliu D, Zhoy L, Kuhnert F, Kuo CJ, Barres BA (2009) Wnt/β-catenin signalling is required for CNS, but not non-CNS, angiogenesis. Proc Natl Acad Sci USA 106:641-646
16. Liebner S, Plate KH (2010) Differentiation of the brain vasculature: the answer came blowing by the Wnt. J Angiogenes Res 2:1-10
17. Lim JC, Kania KD, Wijesuriya H, Chawla S, Sethi JK, Pulaski L, Romero IA, Couraud PO, Weksler BB, Hladky SB, Barrand MA (2008) Activation of β-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem 106:1855-1865
18. Kania KD, Wijesuriya HC, Hladky SB, Barrand MA (2011) Beta amyloid effects on expression of multidrug efflux transporters in brain endothelial cells. Brain Res 1418:1-11
19. Flahaut M, Meier R, Coulon A, Nardou KA, Niggli FK, Martinet D, Beckmann JS, Joseph J-M, Muhlethaler-Mottet A, Gross N (2009) The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/b-catenin pathway. Oncogene 28:2245-2256
20. Schaich M, Kestel L, Pfirrmann M, Robel K, Illmer T, Kramer M, Dill C, Ehninger G, Schackert G, Krex D (2009) A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in GBM patients. Ann Oncol 20:175-181
21. Weksler BB, Subileau EA, Perrière N, Charneau P, Holloway K, Leveque M, Tricoire-Leignel H, Nicotra A, Bourdoulous S, Turowski P, Male DK, Roux F, Greenwood J, Romero IA, Couraud PO (2005) Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 19:1872-1874 (Pubitemid 41598779)
22. Monnaert V, Betbeder D, Fenart L, Bricout H, Lenfant AM, Landry C, Cecchelli R, Monflier E, Tilloy S (2004) Effects of γ- and hydroxy propyl- γ -cyclodextrins on the transport of doxorubicin across an in vitro model of blood-brain barrier. J Pharmacol Exp Ther 311:1115-1120 (Pubitemid 39612718)
23. Siflinger-Birnboim A, Del Vecchio PJ, Cooper JA, Blumenstock FA, Shepard JM, Malik AB (1987) Molecular sieving characteristics of the cultured endothelial monolayer. J Cell Physiol 132:111-117 (Pubitemid 17105330)
24. Campia I, Gazzano E, Pescarmona G, Ghigo D, Bosia A, Riganti C (2009) Digoxin and ouabain increase the synthesis of cholesterol in human liver cells. Cell Mol Life Sci 66:1580-1594
25. Broadley KW, Hunn MK, Farrand KJ, Price KM, Grasso C, Miller RJ, Hermans IF, McConnell MJ (2011) Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme. Stem Cells 29:452-461
26. Liu Y, Yang G, Bu X, Liu G, Ding J, Li P, Jia W (2011) Cell-type-specific regulation of raft-associated Akt signalling. Cell Death Dis 2:e145
27. Carcaboso AM, Elmeliegy MA, Shen J, Juel SJ, Zhang ZM, Calabrese C, Tracey L, Waters CM, Stewart CF (2010) Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas. Cancer Res 70:4499-4508
28. Kopecka J, Campia I, Olivero P, Pescarmona G, Ghigo D, Bosia A, Riganti C (2011) A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells. J Contr Rel 149:196-205
29. Pinzón-Daza ML, Garzón R, Couraud PO, Romero IA, Weksler B, Ghigo D, Bosia A, Riganti C (2012) The association of statins plus LDL receptor-targeted liposome-encapsulated doxorubicin increases the in vitro drug delivery across blood-brain barrier cells. Brit J Pharmacol 167:1431-1447
30. Portnow J, Badie B, Chen M, Liu A, Blanchard S, Synold TW (2009) The neuro-pharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. Clin Cancer Res 15:7092-7098
31. Dalmark M, Storm HH (1981) A Fickian diffusion transport process with features of transport catalysis. Doxorubicin transport in human red blood cells. J Gen Physiol 78:349-364 (Pubitemid 11020899)
32. Ito S, Woodland C, Sarkadi B, Hockmann G, Walker SE, Koren G (1999) Modeling of P-glycoprotein-involved epithelial drug transport in MDCK cells. Am J Physiol 277:F84-F96
33. Goodwin AM, Sullivan KM, D'Amore PA (2006) Cultured endothelial cells display endogenous activation of the canonical Wnt signalling pathway and express multiple ligands, receptors, and secreted modulators of Wnt signalling. Dev Dyn 235:3110-3120 (Pubitemid 44749701)
34. Fu L, Zhang C, Zhang LY, Dong SS, Lu LH, Chen J, Dai Y, Li Y, Kong KL, Kwong DL, Guan XY (2011) Wnt2 secreted by tumor fibroblasts promotes tumor progression in oesophageal cancer by activation of the Wnt/β-catenin signalling pathway. Gut 60:1635-1643
35. Liebner S, Corada M, Bangsow T, Babbage J, Taddei A, Czupalla CJ, Reis M, Felici A, Wolburg H, Fruttiger M, Taketo MM, von Melchner H, Plate KH, Gerhardt H, Dejana E (2008) Wnt/beta-catenin signalling controls development of the blood-brain barrier. J Cell Biol 183:409-417
36. Bernardi H, Gay S, Fedon Y, Vernus B, Bonnieu A, Bacou F (2011) Wnt4 activates the canonical β-catenin pathway and regulates negatively myostatin: functional implication in myogenesis. Am J Physiol Cell Physiol 300:C1122-C1138
37. Tai LM, Loughlin AJ, Male DK, Romero IA (2009) P-glycoprotein and breast cancer resistance protein restrict apical-to-basolateral permeability of human brain endothelium to amyloid-β. J Cereb Blood Flow Metab 29:1079-1083
38. Park CH, Chang JY, Hahn ER, Park S, Kim HK, Yang CH (2005) Quercetin, a potent inhibitor against beta-catenin/Tcf signalling in SW480 colon cancer cells. Biochem Biophys Res Commun 328:227-234 (Pubitemid 40164659)
39. Zhang H, Zhang Z, Wu X, Li W, Su W, Su P, Cheng H, Xiang L, Gao P, Zhou G (2012) Interference of Frizzled 1 (FD1) reverses multidrug resistance in breast cancer cells through the Wnt/β-catenin pathway. Cancer Lett 323:106-113
40. Ananda S, Nowak AK, Cher L, Dowling A, Brown C, Simes J, Rosenthal MA, Cooperative Trials Group for Neuro-Oncology (COGNO) (2011) Phase 2 trial of temozolomide and PEGylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. J Clin Neurosci 18:1444-1448
41. Steiniger SC, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smirnova ZS, Severin SE, Uhl R, Kock M, Geiger KD, Gelperina SE (2004) Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 109:759-767 (Pubitemid 38405625)
42. Wohlfart S, Khalansky AS, Gelperina S, Begley D, Kreuter J (2011) Kinetics of transport of doxorubicin bound to nanoparticles across the blood-brain barrier. J Control Rel 154:103-107
43. Yount G, Yang Y, Wong B, Wang H-J, Yang L-X (2007) A novel camptothecin analog with enhanced antitumor activity. Anticancer Res 27:3173-3178 (Pubitemid 47607539)